𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Anti–prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer

✍ Scribed by Scott T. Tagawa; Himisha Beltran; Shankar Vallabhajosula; Stanley J. Goldsmith; Joseph Osborne; Dan Matulich; Kristen Petrillo; Sarojben Parmar; David M. Nanus; Neil H. Bander

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
233 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Despite recent advances, advanced prostate cancer is suboptimally responsive to current chemotherapeutic agents. Radiolabeled monoclonal antibody therapy that targets prostate‐specific membrane antigen (PSMA) shows promise and is an area of active investigation. J591 is a deimmunized IgG monoclonal antibody developed to target the extracellular domain of PSMA. Preclinical and early phase clinical studies using radiolabeled J591 have demonstrated efficacy in targeting tumor cells and decreasing levels of prostate‐specific antigen. Radiolabeled J591 is well‐tolerated, nonimmunogenic, and can be administered in multiple doses. The dose‐limiting toxicity is reversible myelosuppression with little nonhematologic toxicity. Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti‐PSMA radioimmunotherapy. Cancer 2010;116(4 suppl):1075–83. © 2010 American Cancer Society.

📜 SIMILAR VOLUMES

Prostate-specific membrane antigen (PSMA
Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells
✍ Rena G. Lapidus; Carol W. Tiffany; John T. Isaacs; Barbara S. Slusher 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB 👁 2 views

## Background: Prostate-specific membrane antigen (psma) is a glutamate carboxypeptidase that cleaves terminal carboxy glutamates from both the neuronal dipeptide n-acetylaspartylglutamate (naag) and gamma-linked folate polyglutamate. the prostate enzyme has activity in both the membrane and cytoso

Tumor target prostate specific membrane
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
✍ Arundhati Ghosh; Warren D.W. Heston 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Abstract Prostate specific membrane antigen (PSMA), is a unique membrane bound glycoprotein, which is overexpressed manifold on prostate cancer as well as neovasculature of most of the solid tumors, but not in the vasculature of the normal tissues. This unique expression of PSMA makes it an impo

The fall and rise of prostate-specific a
The fall and rise of prostate-specific antigen: Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer
✍ Gunar K. Zagars; Alan Pollack 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 890 KB

Background. The serum kinetics of prostate-specific antigen (PSA) after radiation therapy for prostate cancer are not well characterized, and the potential prognostic significance of serum half-lives and of serum doubling times is unclear. This study was designed to address those issues. Methods. O

Prostate-specific antigen: A surrogate e
Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?
✍ Schr�der, Fritz H.; Kranse, Ries; Barbet, Nik; Hop, Wim C.J.; Kandra, Albert; La 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 2 views

BACKGROUND. An endpoint for clinical trials of prostate cancer which simplifies traditional endpoints (response of measurable lesions, progression rates, and death) is urgently needed. This is especially true for hormone-unresponsive disease, for which many new drugs are presently in a development p